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The distortions produced by personalized versions of events are well known and 
particularly well illustrated by a number of articles in both the older and more 
recent transplantation literature. Consequently, the student of history will be well 
advised to consult less biased accounts by younger workers such as the catalogue of 
landmarks in renal transplantation provided by Groth of Stockholm after his study 
of the written record and after discussions with most of the workers actually 
involved in the work done from 19500nward.14 
Nevertheless, it may be interesting to describe some of the problems of human 
organ transplantation as they were perceived at the time of our first clinical trials 
15 years ago and subsequently. This has been done first by briefly and incompletely 
sketching the background that had evolved to 1961, the year before the first consis-
tent successes began to be obtained with kidney transplantation. Second, the great 
advances starting in 1962 are described in the second section. Finally, unsolved or 
incompletely resolved problems that still exist 15 years later make up the final 
section. 
THE TWENTIETH CENTURY THROUGH 1961 
The first known attempts at clinical renal transplantation by vascular anas-
tomoses were made without immunosuppression between 1906 and 1923 with 
sheep, pig, goat, and subhuman primate donors. t None of the kidneys functioned 
and the human recipients died from a few hours to nine days later. 
Yet, even in these first cases, some principles were clearly delineated despite 
the climate of ignorance in which the trials were conducted. The applicability of 
vascular suture techniques, the advisability of perfusion of the heterografts to 
remove donor formed blood elements, and even the possibility of using pelvic 
implantation sites were either acknowledged or actually practiced. The efforts to 
use animal organs were abandoned and no clinical renalheterotransplantations 
were tried again until 1963. 
The first human-to-human kidney transplantation was reported in 1936 by 
soronoy~1 who transplanted a kidney from a cadaver donor of B+ blood type to a 
recipient of 0+ blood type in violation of what are now well accepted rules of tissue 
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transfer.· ' Nevertheless, a few drops ofinitial urinary excretion were observed. The 
patient's death 48 hours after transplantation was attributed to a blood transfusion 
reaction. The possibility that there would be an immune barrier to succe~s ~as 
apparently not part of the consciousnes~ of early c~niciansK ~is realiz.anon 
awaited the classical studies ofMedawar with rodent skin grafts which established 
the immunologic basis of rejection. t" 
In the 20 years following Voronoy's case, sporadic additional trials were made 
without the benefit of effective immunosuppression, as recounted 14 years ago by 
Good win and Martin 13 and more recently by Groth." By 1951, Kiiss et aI. H and other 
members of the French school of surgery'" to had virtually standardized the proce-
dure of kidney transplantation to the iliac fo!'sa, anastomosing the renal to the 
pelvic vessels of the recipient in much the same way as is practiced today. Despite 
the lack of success with these early patients, other cases were soon reported from 
Chicago, Boston, Paris, Toronto, London, and Cleveland. * In the meanw~ileI the 
technical soundness of renal transplantation to the pelvic site was unequIvocally 
demonstrated by the identical twin grafting (isotransplantation) experience of 
Murray et aI. 34 
By the middle of the 1950's, the total number of attempts at human renal homo-
transplantation had reached approximately 30 without a~y im~unosuppre~sion at 
all, or with adrenocorticotropic hormone (ACTH) or cortisone In a few patients of 
Kiiss et al.,n Dubost et a1.,11 and Hume et aI.,a Most of the homografts never ~ad 
significant function, and those that did initially, usually underwent prompt reJec-
tion, as was reported particularly clearly by Michon et aI. 30 qhe~e were three more ~~ 
less clear exceptions to this generalization. Renal homogr~ts Inserted by Lawle.r, 
Gordon Murray,al and Hume'· and their colleagues were sald to h~ve e~creted unne 
for several months before being rejected slowly. The life ofHume s patient probably 
was increased thereby by several months. The unexpectedly prolonged survival ~f 
kidneys in untreated recipients has been explained since by. the loss ofimmunologIc 
responsiveness that has been shown to accom~any u~emlaK . . 
In the meanwhile, the deliberate obtundatIOn of ImmunologIC reac~lvity be-
came theoretically feasible when total body irradiation was shown to be Immuno-
suppressive. 10." After that, an intermediate era in renal transplant~tion was be~un 
in 1958 by Joseph Murray and his associates at the Peter Bent. Bngham Hospital 
using total body irradiation as the primary m~ansK to preve!lt reJectIOn."" ~lthou~h 
most of the recipients died, two patients are still alive who, In 1958, were gIven kId-
neys in Boston33 and in Paris" from fraternal twin donors .. kev~rt~elessI the great 
risks and highly unpredictable effectiveness of total body f~a~ation a~ the sole or 
main modality of immunosuppression made the undertaking lffipracucal. 
The transplantation explosion which eventually occurred from 1962 onward 
was dependent upon the use of drugs. The first and, asi~ turned out, mostim~rtant 
class of agents was the steroids. The experimental baSIS for the use of sterOIds was 
laid in 1951 by Billingham, Krohn, and Medawar".with pro~mt confirm~tionKby 
others. The second seminal development was the mtroduction of the ~hllpunne 
compounds, 6-mercaptopurine and its imidazole derivative, azathiopnne. Thes.e 
agents were developed by Dr. George H. Hitchings and Gertrude Elion and their 
colleagues at Burroughs Wellcome and Company,Inc., Tuckahoe, New York, a.nd 
found by them to inhibit hemagglutinin formation in mice challenged with 
heterologous red blood cells. 17 
In 1959 the action of thiopurine compounds in blunting the immune response 
to bovine se.:.um albumin was reported by Schwartz andmamesh~kP"in the journal, 
Nature. By the time of publication, the authors had m press m The Journal of 
Clinical Investigation a second article which doc~m~nte~ t~e effect of 
6-mercaptopurine upon rabbit skin homografts. 3. Mean regectfl~ time f~ 16 control 
animals was 6.8 days compared to 17.8 days in a group of 17 anlffials gIven 12 mg 
per kg per day of 6-mercaptopurine for 2 weeks, and the same dose every other day 
thereafter. ]n this important study, dose response curves were also defined. The 
work was presented at an international ~ongress in. ioD:ldo~ onK~emtember 7., 1959. 
The findings were promptly confirmed m another mstltutlon. A furt!ler aifirma-
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tion of the antirejection qualities of 6-mercaptopurine came shortly afterward 
when it was tested by Caine' with the canine kidney model. Two mongrel dogs in 
this latter study survived for 21 and 47 days after renal transplantation from 
nonrelated donors and after bilateral recipient nephrectomy. The number of exper-
iments were not stated nor were there controls. Further information was provided 
in later publications by Caine for 6-mercaptopurine and azathioprine.' 
As recounted by Groth" a number of patients in Europe and the United States 
were given one or the other of the mercaptopurine drugs between 1959 and 1962, 
usually with a fatal outcome. However, two French recipients survived for pro-
longed periods of time. One who lived for 17 months was treated in 1960 by Kuss 
and his colleaguesU with 6-mercaptopurine after initial total body irradiation, and 
the other was managed silllilarly by Hamburger and aBsociates"in January. 1962. 
By 1973, Hamburger's patient, whose donor was a cousin, had become the lonlelt 
surviving non-twin recipient in the world. Murray et aI.s• reported the first patient 
in whom prolonged survival was achieved under primary immunosuppression with 
azathioprine alone; this recipient of a cadaver kidney lived for almost 2 yean.-
However, even well into 1962, there was little evidence that drug therapy would 
yield results substantially better than those obtained with total body irradiation. 
Such impro.vements would await the administration of drugs in combination (see 
next section). 
My own involvement in transplantation began in the summer of 1958 at 
Northwestern University in Chicago. While a new method for one-stage hepatec-
tomy was being developed in dogs, it was appreciated how easy it would be to 
replace the liver with a graft using a temporary portacaval shunt with or wi thoutan 
external bypass to decompress the blocked splanchnic and systemic circulations. 
At about this time, I had decided to remain in university work in preference to 
entering private practice and had spent several weeks in the medical library trying 
to decide upon some broad area of research in which to make an investment. 
Transplantation seemed a worthwhile challenge, partly because of the deeply 
pessimistic attitudes that prevailed about the prospects of clinical organ transplan-
tation in any except the most unusual cases such as those involving fraternal twins. 
Transplantation of the liver was especially appealing at that time because of its 
technical challenge. 
Another factor that gave the liver special interest was speculation by Dr. Jack 
Cannon of Los Angeles that the liver played an important role in rejection. Because 
of this, Cannon, who was the first to attempt liver replacement, 7 apparently hoped 
that a hepatic homograft might suffer a different fate from that of other trans-
planted tissues since it presumably would not contribute to its own repudiation. As 
it turned out the liver has seemed to be less susceptible to rejection than any other 
major organ but for reasons that are still not understood.·' Between 1958 and 1962 
in the experimental liver transplant program which I established in Chicago, a 
brief attempt was made to irradiate both the graft and the recipient; prolongation of 
graft survival was not obtained. 
THE KIDNEY FROM 1962 ONWARD 
The kind of laboratory research with steroids, 6-mercaptopurine and azathio-
prine mentioned above was applicable in one way or another to organ replacement 
in man, but the connection was not straightforward. In occasional dogs a protracted 
life proved possible after renal transplantation with the use of steroids ,03 
6-mercaptopurine,37 or azathioprine" 36 ... as the sole immunosuppressive treat-
ment. In man occasional similar successes were occasionally achieved solely with 
6-mercaptopurine or azathioprine as was mentioned earlier. Nevertheless, the 
consistency with which really long-term survival was obtained was poor. The 
obvious reason was that complete control of rejection was rarely achieved. 
Thus both the animal data and the initial clinical experience discouraged 
further trials. The most important development which made immunosuppression 
practical was the discovery of the way in which azathioprine ana prednisone could 
be advantageously used together. There were essentially no preceding laboratory 
data to indicate that the benefit with this now universally accepted combination of 
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agents would be as great as proved to be the case. Indeed, the first publication on 
experience in animals" was a belated confirmation of the far more convincing 
observations already made in humans." 
Furthermore, it is difficult even in retrospect to ascribe priority for standardiza-
tion of azathioprine-steroid therapy to any single authority or transplantation 
group. What is clear is that by early 1963 the two drugs were being used together in 
one way or other and with varying degrees of conviction about their synergism for 
the prevention or reversal of renal homograft rejection in at least one British".and 
three American centers.'·' 3 •••• Since then, variations of these regimens have been 
adopted throughout the world. 
The way in which our own initial efforts in renal transplantation evolved was 
as follows. Shortly before I came to the University of Colorado in late 1961, a 
27 year old man suffering from terminal renal disease was seen at the Denver 
Clinic by Dr. Philip Clarke. Dr. Clarke discussed the case with Dr. William R. 
Waddell, who had com e to Colorado in July, 1961, as Professor and Chairman of the 
Department of Surgery. After my arrival at Christmastime, 1961, Dr. Waddell 
arranged for me to see the patient and because of my interest in transplantation he 
asked me to organize an interdiSciplinary treatment team. Fortunately, the recip-
ient had an identical twin. The transplantation was carried out on March 27, 1962. 
Dr. Robert Brittain performed the donor nephrectomy. I performed the recipient 
operation with the assistance of Drs. Oliver Stonington, Richard J. Sanders, and 
William R. Coppinger. 
While this first patient was still recuperating, a second recipient who did not 
have the advantage of a genetichlly identical donor was admitted to the hospital in 
renal failure. The month was May, 1962. Chronic dialysis was not yet a well 
established form of treatment. On acute intermittent hemodialysis the access 
vessels were rapidly consumed in this and other early patients. At the same time, 
desperate efforts to develop effective immunosuppressive treatment with total 
body irradiation and azathioprine were carried out in the laboratory of the Denver 
Veterans Administration Hospital. Completely acceptable results in dogs could not 
be by either irradiation or azathioprine alone or, for that matter, when they were 
used in combination. 
Nevertheless, the decision was made to proceed with transplantation of this 
12 year old patient since the prospects of further dialysis treatments were dismal. 
The plan was to give 300 R total body irradiation preoperatively, 100 R more 
postoperatively, and to supplement this treatment with azathioprine as the bone 
marrow depression recovered. The treatment schedule was similar to that used by 
Murray"" and Hamburger" for their fraternal twin cases. If rejection OCCUlTed 
steroid therapy was planned. 
The course of that first patient is summarized in Figure l. The kidney which. 
was donated by the boy's mother functioned well initially but after two weeks a 
severe rejection developed in spite of the fact that there were virtually no circulat-
ing white blood cells. The BUN rose to more than 75 mg per 100 ml and the 
creatinine clearance fell to about 5 ml per minute. Prednisone in daily doses of as 
high as 150 mg was added and daily doses of azathioprine were cautiously added 
about two weeks later. 
Although the rejection was thereby reversed with survival of the patient to the 
present time, the frightening experience with total body irradiation and conse-
quent bone marrow depression convinced us that the irradiation should be omitted 
on the next occasion. In the following 44 cases" azathioprine was started shortly 
before operation and continued in the maximum doses that were thought to be pos-
sible without the production ofleukopenia. Prednisone was withheld until graft re-
pudiation had clearly started. In retrospect, the most important advantage of with-
holding steroids until a specific indication was that the features of rejection and 
host-graft adaptation, as well as the influence of drug therapy on these processes 
(see below) could be delineated with some precision. The greatest disadvantage 
was that the rejections which developed under treatment with azathioprine alone 
were sometimes very severe and difficult to reverse with delayed steroid therapy. 
It was found that their incidence and seriousness were reduced if prednisone was 
given from the beginning." Consequently, it has been our policy since December, 
1963, to immediately treat virtually all recipients of organ homografts with predni-
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Figure 1. Rejection crisis in patient (LD 1) treated initially with total body irradiation (400 
R). Note transient oliguria, depression of creatinine clearance, and elevation of blood urea 
nitrogen, blood pressure, and urinary protein excretion. The changes were all reversible. The 
patient previously had undergone bilateral nephrectomy, splenectomy, and thymectomy. R, 
dose total body irradiation; Acti-C, actinomycin C (each arrow equals 200 p.g of actinomycin C 
administered intravenously). lmuran is synonymous with azathioprine. These eeneral events 
of rejection have occurred despite treatment with all the therapeutic regimens used at this and 
other centers since 1962. (From Stan!, T. E .• et al. : The reversal of rejection in human renal 
homografts wilh subsequent development of homograft tolerance. Surg. Gynecol. Obstet., 
117:385, 1963, with permission.) 
sone and azathioprine (sometimes cyclophosphamide has been used instead of 
azathioprine), to which in recent years heterologous antilymphocyte globulin 
(ALG) has been added in a triple drug program. 
By the spring of 1963, the practical possibilities of clinical renal transplanta-
tion had already become obvious from observations of our first patients. One reason 
was \he repeated demonstration that rejection was a highly controllable and re-
versible process. The first report to this effect began as follows:" 
"Because of the high failure rate after renal homotransplantation, there 
has been an air of pessimism concerning the possibility oflong term function 
of the grafted kidney, The immunologic processes subserving rejection are 
generally thought to be so powerful and persevering that consistent success 
cannot be expected with the use of any of the currently available methods of 
antirejection therapy. 
"Recent personal experience in caring for patients with renal homo-
grafts has resulted in alterations in many of our preconceived notions con-
cerning the management of such patients. It has led to the beliefs that the 
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Figure 2. Classic rejection crisis in patient (LD 6) treated with drugs alone. Deterioration 
of renal function began 19 days after transplantation. All stigmata of rejection are present 
except for acute hypertension and weight gain, which were successfully prevented by medical 
trearment. Acti-C, actinomycin C; LN ,left nephrectomy at time of transplantation; RN, Right 
nephrectomy. Imuran is synonymous with azathioprine. (From Stanl, T. E., et al.: The rever-
sal of rejection in human renal homografts with subsequent development of homograft toler-
ance. Surg. Gynecol. Obstet., 117:385, 1963, with pennission.) 
rejection process can almost never be entirely prevented, but that its effects 
can be reversed with a high degree of regularity and completeness. Further-
more, the subsequent behavior of patients who have been brought through 
a successfully treated rejection crisis suggests the early development of some 
degree of host-graft adaptation, since the phenomenon of vigorous secondary 
rejection has been encountered only once." 
In that series there were 10 patients treated in late 1962 and early 1963. In seven, 
including the first one treated with irradiation and mentioned earlier, clear cut re-
jection of variable intensity occurred from 4 to 34 days after operation (Fig. 2), in 
one case actually leading to anuria. In each instance, the process was reversed by 
the addition of massive doses of prednisone to the pre-existing therapy with aza-
thioprine (Fig. 2). Three of these seven patients are still alive 14 or more years later 
and are now among the longest living recipients of non-twin homo grafts in the 
world. After the remarkable effectiveness of steroid therapy in this situation had 
been established from our own experience, but before our findings were published, 
it was learned that the same kind of observation had been made by Goodwin and his 
associates" in a young woman who ultimately died of sepsis 144 days after receipt 
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The reversibility of rejection in these patients was only one of the features 
which established the clinical feasibility of organ transplantation. The quantities 
of adrenal corticosteroids necessary to achieve reversal were often too large to be 
compatible with long survival of the recipient if continued indefinitely. Fortu-
nately, another event of equal practical importance transpired coincidentally with 
the reversal of rejection or shortly afterwan:l. With the passage of time, the need for 
intensive therapy usually diminished both in patients who did and those who did 
not pass through a clinically evident rejection. Thus, the patient whose course is 
depicted in Figure 2 had returned within five months after transplantation to 
treatment only with azathioprine, a drug which at the outset did not prevent the 
onset of a moderately severe rejection. An ultimate similar reduction in drug re-
quirement is seen today in almost all new successfully treated recipients and it is 
probable that some patients could eventually have all therapy stopped. In our 
laboratory, we have had dogs live for 10 to 12 years after being given treatment with 
immunosuppressants only for the first four postoperative months. 
The foregoing phenomenon of graft acceptance is not understood (see discus-
sion in reference 42, p. 229). However, there is little reason to doubt that a homo-
graft becomes more orJess privileged if it can be kept alive through the initial 
onslaught of rejection. This fact is at least partly responsible for the shape of life 
survival curves after renal homotransplantation in that the preponderant mortality 
is in the first few postoperative weeks or months when stringent immunosuppres-
sion is required. I t has strongly influenced the way in which new therapeutic agents 
such as heterologous anti! ymphocyte globulin (ALG) have been used clinically, and 
it has been a prime stimulus for the extension of transplantation techniques to 
organs other than the kidney in which both reversal of rejection and "adaptation" 
are not very different from what they are with the kidney. 
In any event, the numbers of successful cases grew rapidly during the spring 
and summer of 1963. By the first week of September, 1963, when an international 
meeting was convened at the National Research Council, 2101 Constitution 
Avenue, Washington, D.C., to consider the past and future of renal transplantation, 
our Colorado series of kidney recipients was up to 27. In preparation for this meet-
ing on September 26 and 27, 1963, the 2Y2 x 3Y2 foot wall flow sheets from all of 
these patients were gathered together with the aid of Tom Marchioro, now Pro-
fessorofSurgery at the University of Washington, Seattle, and bound between soft 
leather covers like Egyptian scrolls. These were carried by Bill Waddell and me to 
Washington. 
I remember the surprise, ifnotincredulity, that greeted our report of a very high 
survival rate (20 of the 27 patients were alive) with so many examples of essentially 
normal renal homograft function. The book of flow sheets promptly found itself on 
the center conference table under close scrutiny. The recorded proceedings of the 
meeting contained much lively, provocative and friendly discussion which would 
ha ve made interesting reading, but very little of the spirit of that meeting survived 
to make its way into print.'M 
On the last evening of the conference, Dave Hume of Richmond and Kendrick 
A. Porter of London came to my hotel room. We spent almost all the night going over 
each of the Colorado cases. As soon as the meeting finished, Porter and Roy Calne 
came to Denver where a further exchange of information and ideas took place. 
Realizing the unique value of our cases, I had already started to write a book 
based on the University of Colorado clinical material. Before he left Denver, Ken 
Porter had agreed to prepare a section on the histopathology of renal homo-
transplantation. His chapter became a monograph in its own right (see reference 
41, pp. 299-359) to which surprisingly little has been added in the intervening 
years. Porter and I have maintained a fruitful collaboration since then. 
By the time the book was finished the following May, the series had increased to 
64. Today with follow-ups of 13 to almost 15 years, about one-half of that Original 
group are still alive. A great number of original observations were made possible by 
the chance to watch this bellwether group of patients and those were summarized 
in the book. The operative techniques for renal transplantation in adults as well as 
children were standardized. The rules of acceptable transfer of tissues between 
donors and reCipients of different blood types were established, and it was shown 
that violation of these rules could lead by the action of prefonned recipient an-
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tibodies (in this case isoagglutinins) to what later became known as "hyperacute 
rejection." The first widely used techniques of organ preservation were introduced, 
consisting of cooling of the excised organs by infusion with cold solutions. More 
sophisticated methods of preservation, including cadaveric whole body perfusion, 
were introduced. The requirements and techniques of infectious disease control 
were standardized. A limited, informative, but ultimately unsuccessful trial of 
renal heterotransplantation using baboon kidneys was undertaken. A comparison 
of the fate -of these baboon heterografts with that of Reemtsma's chimpanzee 
heterotransplantations show that the chimpanzee would be a better donor if 
animals are used for this purpose in the future. 
By the spring of 1964, the basic care of kidney recipients under double drug 
immunosuppression had been standardized in much the mold that is so familiar 
today. Further developments have occurred. Most importantly, the supply of high 
quality organs has been greatly increased by the wide acceptance of irreversible 
brain injury as the ultimate definition of death rather than the cessation of 
heartbeat." . 
The importance of these changes in social and legal attitudes has been am-
plified by research in organ preservation. In 1967, Belzer and his associates in San 
Francisco described ex vivo perfusion methods with plasma derivatives that al-
lowed the preservation of kidneys for two or three days. a Not long after simple flush 
techniques using cold electrolyte solutions ofintracellular composition (containing 
high potassium and high magnesium) were introduced that allowed successful 
refrigeration for 24 to 48 hours.' With these improvements in organ preservation, 
renal transplantation became an elective undertaking in comparison to the urgent 
conditions which had been necessary before. 
In tissue typing, there were great expectations in the middle and late 1960's. 
The first retrospecti ve as well as the first prospective attempts at HL-A tissue typing 
in kidney recipients were inaugurated in a collaboration with Dr, Paul Terasaki of 
Los Angeles. 5C! Unfortunately, the fuzzy correlations of HL-A matching and the out-
come in all except perfectly matched sibling cases indicated that the tissue typing 
issue was much more complex than had been appreciated. The use of tissue 
matching to identify good sibling combinations has been useful. But bm a practi-
cal standpoint the most important matching procedures today are the direct cross-
matches which avoid placing a kidney into a recipient who possesses pre-
formed antigraft antibodies. The first lessons about the harmful effects of pre-
formed antibodies were learned with blood group mismatches in which antired cell 
isoagglutinins triggered hyperacute rejection." Not long after, the devastating 
effects of preformed cytotoxic antibodies were described by Terasaki et al.·· and 
Kissmeyer-Nielsen et al. 11 
In 1966, we introduced what has since been called a triple drug program of 
immunosuppressive therapy adding antilymphocyte globulin (ALG) to azathio-
prine and prednisone. ALG consists of antibodies raised in animals against human 
lymphocytes. The regimen of ALG which was used in man was guided by several 
general conclusions that emerged from the experimentations with large animals in 
our laboratories and elsewhere ... ·•• These can be summarized as follows: (1) ALG 
had potent but imperfect immunosuppressive qualities when used alone; (2) with 
continued administration of the heterologous serum derivatives there was a highly 
significant risk from a variety of foreign protein reactions; and (3) ALG could be 
used effectively and probably with increased safety in combination with other 
drugs. Each of these factors contributed to the initial decision to employ heterolo-
gous ALG as an adjuvant agent added to therapy with azathioprine and prednisone 
and to limit its use to the first tour postoperative months. It was hoped that the 
predictability and safety with which homograft rejection could be prevented would 
thereby be improved and that the hazards of immunologic reactions to the serum 
products would be accordingly reduced with the efficient level of immunosup-
pression to which all three agents would contribute. 
These basic tenets have been used in all the modifications of the triple agent 
program that have been used since that time. The original trial of the ALG was 
given intramuscularly but the intravenous route is usually used now. Questions are 
incompletely answered about the best kind of lymphoid antigen and the most 
'llmronriat(' :mimal in which to raise the antilymphocyte antibodies as well as the 
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Table 1. Experience with Renal Transplantation at the University of 
Colorado, 1962-1975 
NO. OF CASES 
FOllOW-UP 
Re- Un- TO AUG 1976 
SERIES lated related" DATES (YEARS) MAINFEATUU 
46 18 Nov 1962 1211.-13* Azathioprinelprednisone; 
to Mar 1964 good risk 
2 25 23 tOct 1964 1011.-1 PI. Azathioprine/prednisone 
to Apr 1966 + typing; good risk 
3 60 17 June 1966 8Va-10'/. Azathioprinelprednisonei 
to Feb 1968 ALG; good risk 
4 122 15 Mar 1968 5'h-8Va Azathioprinelprednisone/ 
to Mar 1971 ALG; all risk 
5 44 28 Mar 1971 4-5lr2 Cyclopbospbamidelpred-
to Aug 1972 nisone/ALG; all risk 
6 65 49 Aug 1972 2-4 Azathioprinelprednisone/ 
to Aug 1974 ALG; all risk 
7 27 17 Sept 1974 1-2 Azathioprine/prednisOne/ 
to Aug 1975 ALG; all risk 
'Slnce 'ate 1965, all unrelated kidneys bave come from cadavers. Before then, non-
related volunteer donors were used. . 
correct dose and timing of the ALG (see discussion in reference 42, pp. 207-216). 
For that matter, a number of authors have contended that ALG does nothing in im-
proving immunosuppression that could not be achieved equally by the clever mani-
pulation of steroid and azathioprine doses. 
In spite of this skepticism, most of the reports of controlled studies with ALG 
have shown a higher rate of kidney survival, fewer rejections and at least equal 
patient survival. At the International Transplantation Society meeting in Sep-
tember, 1976 (New York City), there was a stronger consensus than at any time in 
the preceding decade that ALG was a useful clinical adjunct. 
The only other major immunosuppressive agent that has been used extensively 
has been cyclophosphamide. In 1970 and 1971 we showed that in large series in 
which,cyclophosphamide replaced azathioprine as part of a double or triple drug 
program, the results were essentially the same with either drug." Although the 
results were no different from those obtained with azathioprine, we have since 
returned to the rou tine use of azathioprine bec ause of our much greater experience 
with it and because of our high degree of satisfaction with its use. 
Table 2. Actual Survival at One Year and ThereafteT in Patients 
Given Primary Related Grafts from 1962 to 1975 
PER CENT SURVIVAL 
NUMBER 2 4 8 10 
SERIES OF CASES Year Years Years Years Years 
1 46 67 65 61 57 52 
2 25 64 64 52 40 40 
3 60 92 88 78 67 
4 122 76 73 68 
5 44 86 80 74 
6 65 77 75 
7 27 89 
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Table 3. Actual Survival at One Year and Thereafter in Patients 
Given Primary Nonrelated Grafts from 1962 to 1975 
PER CENT SURVIVAL 
NUMBER 2 4 8 10 
SERIES OF CASES Year Years Years Years Years 
1 18 33 22 17 11 11 
2 23 52 43 30 17 13 
3 17 82 76 41 29 
4 15 80 80 80 
5 28 75 75 61 
6 49 82 71 
7 17 94 
The immunosuppressive protocols developed at the University of Colorado and 
the patients treated are listed in Table 1. The results of this experience brought up 
to date to August, 1976, were presented at the 1976 meeting of the International 
Transplantation Society, have been recently published, and are summarized in 
Tables 2 and 3. The greatest improvement in recent years has been survival after 
cadaveric transplantation (Table 3) and, in tum, this is explained by a greater 
willingness to abandon an initial homograft and to consider return to dialysis or 
retransplantation. At the present time, reCipients of either related or unrelated 
homografts are surviving for one year at about an 80 to 90 per cent rate and about 
three-fourths are still alive at the end of 4 years. 
CLINICAL LIVER TRANSPLANTATION 
Looking back at the Colorado scene of the early 1960's, it was inevitable that 
transplantation oCthe liver would be performed. Optimism was high because of the 
success of double drug immunosuppression in controlling renal homograft rejec-
tion. The assumption was made that the same therapy would be applicable for other 
organs. a view that was proved correct both in animals and man. U Finally, the 
ability to carry out liver transplantation had been assiduously developed in J:,e-
search involving hundreds of dogs during the preceding 5 years and was known to. 
be within our technical capability. Thus. a policy decision was made in early 1963 
to proceed with orthotopic liver transplantation. an operation which requires re-
moval of the diseased native organ and its replacement with a cadaveric graft (Fig. 
3). 
The first 4 attempts were made in 1963 on March I, May 5, June 24, and July 
16. A fifth patient was treated by Francis Moore in Boston on September 16, 1963, 
followed by another in Denver on October 4, 1963 (all early cases in Denver and 
elsewhere are catalogued in reference 42, pp. 530-532). 
Our first recipient bled to death during the operation; the other 4 first Denver 
patients survived operation but died from 61/2 to 23 days later. Success was nearly 
achieved in some of these cases." For example, our second patient. a 48 year old 
male with cirrhosis and a hepatoma, was in remarkably good condition postopera-
tively. He died 22 days later of systemic and pulmonary infection. At autopsy there 
were no serious complications in the abdominal cavity. The liver had no un-
equivocal findings of rejection. Biliary duct reconstruction with 
choledochocholedochostomy over a T-tube was satisfactory (Fig. 3). Portions of 
both lungs were necrotic. The pulmonary arteries contained multiple old clots. 
Apparently, these were deposited at the time of operation from a plastic bypass 
tubing that had been used to return blood from the vena caval and splanchnic 
venous pools while these systems were obstructed during the intraoperative 
anhepatic phase. Ironically. it was later proved that such temporary bypasses are 
unnecessary because of the well developed venous collaterals in end-stage liver 
nisf':lsf' .•• 
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The series of consecutive early failures caused a moratorium of 3 years to be 
declared on further cases. Only one more patient was treated at our center until the 
summer of 1967. The justification to then start another series came from experi-
ence with the triple drug immunosuppressive program (including ALG) which by 
then seemed to be helping the kidney recipients. On July 23, 1967, the chance 
presented to treat a 11f2 year old girl who had a hepatoma. She lived through the 
operation ofliver replacement and for 13 months afterward before finally dying of 
widespread tumor metastases. Each of the next 8 recipients lived for at least 2 
months postoperatively. and 3 of these 8 lived for more than one year with the 
longest survival of 29 months and 16 days. 
The first 25 liver recipients in the Colorado series eventually provided the 
experience for a text of liver transplantation .•• Fi ve of these 25 patients lived a year 
or more. The feasibility stage of human liver transplantation had been passed, but 
with a one-year mortality of 80 per cent, widespread exploitation of the procedure 
was a long way off. . 
Nor was there a quantum improvement in the succeeding 7 years. The patients 
surviving for one year in the second, third, and fourth groups of 25 patients each 
were only 6,8, and 9, respectively. However, one of these reCipients isnow 71f3 years 
postoperative and a total of 6 have lived more than 5 years; 5 of these 6 are still 
alive. 
During a sabbatical leave in 1975 and 1976, I had an opportunity to live in 
London and to work with Profeslior K. A, Porter whose collaboration wall described 
earlier in this article. Together, we reviewed the first 93 cases of orthotopic liver 
transplantation and tried to recatalogue the main reasons for failure. Our con-
clusions were that:" (1) uncontrolled rejection was a relatively uncommon cause of 
mortality; (2) technical mistakes and mechanical problems with the homografts 
accounted for the greatest numbers of deaths; and (3) if the complications were of 
duct reconstruction they frequently caused untreatable infections. 
Figure 3. Orthotopic liver transplantation with biliary duct reconstruction by 
choledochocholedochostomy after cholecystectomy. Other acceptable techniques of biliary 
reconstruction involve anastomosis of the homograft gallbladder or common duct to a Raux-Y 
;""ma\limh. 
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.Bett.er manage~ent guidelines were developed based on more accurate diag-
nOSIS WIth emphasIS on frequent needle biopsies and transhepatic cholangiog-
raphy, avoidance of overimmunosuppression while using the triple drug therapy, 
and better technical performance at the original operation. The most fundamental 
technical adjustment was to perform biliary duct reconstruction with 
choledochocholedochostomy over aT-tube stent (Fig. 3), or by anastomosis of a 
Roux-y jejunal limb to the graft gallbladder or common duct. The various changes 
were completed and standardized by late spring, 1976. 
.Since then, 19 more patients have had liver replacement. With follow-up 
penods of3 weeks to 12 months, 14 of the 19 recipients are alive. The 4 postopera-
tive deaths have been due to rejection (one example), inability to revascularize the 
liver due to recipient portal vein thrombosis (one example), subhepatic infection 
with erosion into the hepatic artery (one example), bone marrow depression with 
pneumonitis (one example), and uncontrollable heart failure (one example). The 
expectation now is that more than one-half and possibly as many as two-thirds of 
~he modem day liver recipients are going to survive to the one-year mark. The same 
Improvement in recent results has been noted also by Calne and Williams working 
in England." 
One of the major by-products of liver transplantation has been new insight 
about the effect of portal blood and its so-called hepatotrophic constituents on liver 
structure, function, and the capacity for regeneration. This new area of research 
was opened during inquiries into the optimum means ofrevascularizing auxiliary 
liver homografts while leaving the native organ in place.23 The essence of portal 
hepatotrophic concept is thafthe liver is controlled or influenced profoundly by 
hormones coming from the venous effluent of splanchnic viscera into the portal 
vein. Insulin is the most influential of these hormonal factors, although not the only 
one. From a practical point of view and as it relates to transplantation, the implica-
tion is that the portal vein of an auxiliary liver should be supplied with splanchnic 
venous blood if it is to have an optimal chance of survival. 
Auxiliary liver transplantation was first attempted in humans by Absolon et al.' 
and was also given a brief trial at our center. 4. The only person to definitely benefit 
from this procedure so far has been a child cared for by Dr. Joseph Fortner of New 
York who is now 4 years after auxiliary transplantation for biliary atresia. We have 
not performed this operation for several years. 
OTHER ORGANS 
The dramatic extension of basic transplantation concepts to heart replace-
ment, lung transplantation, and pancreatic transplantation are well known and 
beyong the scope of this article. We have carried out 7 heart transplantations with 
the longest survival of 29 months. Several years ago, a decision was made not to do 
more cardiac cases since our trials did not add to the developmental efforts of the 
Stanford team headed by Norm Shumway and Ed Stinson. 
Unresolved Problems 
The great wave of successful renal transplantations in the early 1960's and the 
prompt demonstration that extrarenal organs could also be transplanted in 
humans led to a mood of exhilaration seldom tempered by a cautionary note. Al-
though the situation was acknowledged to be imperfect, it was widely believed that 
new and fundamental developments with which to correct any deficiencies were 
close at hand. Indeed, as was already stated, many advances were subsequently 
made in surgical techniques, in organ preservation, and in understanding the 
complexities and limitations of tissue typing. 
However, growth arrest has occurred in the one area that gives transplantation 
uniqueness and that is central to a myriad of complications which organ re-
Cipients must still face. The main problem area remains immunosuppression and 
from this combined with the impracticality of donor selection by tissue typing 
stems two therapeutic deficienCies. 
. First, the predictability of treatment is imperfect. A reasonably accurate prog-
nosIs can be offered only to recipients of perfectly matched sibling kidneys. But 
" 
" \ 
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even here there is an occasional unexpected graft loss from rejection that cannot 
easily be explained despite intensive retrospective study. Using relatives other 
than perfectly matched siblinl donors, the predictability ofrejection control is sub-
stantially less. When cadaveric organs are tranlplanted, lome patientl have un-
controlled rejection, others have no difficulty at all, and about half are intermediate 
between these extremes. Although the exact success rate after cadaveric kidney 
transplantation is influenced to some extent by the inclusion or exclusion of candi-
dates who have a high risk because of advanced age, coincident disease, or other 
factors, kidney survival at one year using any of the presently employed regimens 
is seemingly more or less fixed at about 50 to 70 per cent in all the world's great 
transplantation centers. 
The second general defect is related to the first. At the present time, even pa-
tients who eventually achieve a perfect transplant result often must first pass 
through a postoperative period of significant morbidity. The requirement forinten-
sive immunosuppression is greatest early after transplantation. Because the 
steroids are the only highly dose-maneuverable component of the immuno-
suppressive regimens presently employed, the intensification of therapy translates 
inevitably into larger quantities of prednisone. If high-dose steroid therapy can be 
avoided or kept to a brief duration while at the same time maintaining good homo-
graft function, the result is apt to be spectacularly successful. If steroids are needed 
chronically, their well-known side effects depreciate the value of post-trans-
plantation life or may threaten survival itself if the doses are too high. 
Although the drug combinations that include azathioprine, prednisone, 
cyclophosphamide, and ALG have evolved into well standardized double- or triple-
drug cocktails that have been used the world over, all are variations on the same 
theme. Further small adjustments in dosage and schedule are not going to correct 
the deficiencies of transplantation just mentioned. Some drastic changes in ap-
proach are going to be needed. The objective is a foreshortening of the graft ac-
ceptance process, so that the transplant passes through the danger period in a few 
days instead of a few weeks or months. . 
The first step to accomplish this is to acknowledge that our present methods of 
treatment represent only a halfway station toward an acceptable final regimen. 
Some kind of tolerance induction or the effective use of enhancement procedures 
might be made easier if better drugs were found but no hint of a breakthrough in 
any of these areas is evident at present. 
Nevertheless, a high order of patient service can be provided today with renal 
transplantation despite the limitations ofimmunosuppression. The reason is that it 
is so easy to return patients to chronic dialysis if too much immunosuppression is 
required to retain homograft function. The same is not true for the liver, heart, and 
lung, for which artificial organ backup is not available. Using these organs, trans-
plant and patient survival are nearly synonymous. 
With the heart, the transplantation itself presents no troublesome technical 
problems, and in Shumway's magnificent series the life-survival curve reflects very 
accurately the ability to control cardiac rejection. The one-year survival has edged 
up to above 50 percent in the Stanford series. As described earlier, a similar steady 
improvement has been seen with the immunologically easier but technically more 
difficult liver. Very little work is now going on with the lung. 
With both the liver and lung, it is unlikely that a clear distinction between 
technical, infectious, and rejection problems will be possible until a much more 
reliable method is available for the promotion of graft acceptance. Then if some-
thing goes wrong it can be assumed that rejection is not the cause. Today the 
obverse assumption that rejection is responsible must always be made. 
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